99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice

Alexis Broisat*1,2, Jakub Toczek*1,2, Laurent S. Dumas1,2, Mitra Ahmadi1,2, Sandrine Bacot1,2, Pascale Perret1,2, Lotfi Slimani1,2, Gilles Barone-Rochette1–3, Audrey Soubies1,2, Nick Devoogdt1, Tony Lahoutte4,5, Daniel Fagret1,2, Laurent M. Riou1,2, and Catherine Ghezzi1,2

1Unité 1039, INSERM, Grenoble, France; 2Radiopharmaceutiques Biocliniques, Université Joseph Fourier Grenoble 1, Grenoble, France; 3Cardiology Department, Grenoble University Hospital, Grenoble, France; 4In vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel (VUB), Brussels, Belgium; and 5Nuclear Medicine Department, UZ Brussel, Brussels, Belgium

99mTc-cAbVCAM1-5, a single-domain antibody fragment directed against mouse or human vascular cell adhesion molecule 1 (VCAM-1), recently has been proposed as a new imaging agent for the detection of inflamed atherosclerotic lesions. Indeed, in a mouse model of atherosclerosis, 99mTc-cAbVCAM1-5 specifically bound to VCAM-1-positive lesions, thereby allowing their identification on SPECT images. The purpose of the present study was to investigate 99mTc-cAbVCAM1-5 imaging sensitivity using a reference statin therapy.

Methods: Thirty apolipoprotein E-deficient mice were fed a western-type diet. First, the relationship between the level of VCAM-1 expression and 99mTc-cAbVCAM1-5 uptake was evaluated in 18 mice using immunohistochemistry and autoradiography. Second, longitudinal SPECT/CT imaging was performed on control (n = 9) or atorvastatin-treated mice (0.01% w/w, n = 9). Results: 99mTc-cAbVCAM1-5 uptake in atherosclerotic lesions correlated with the level of VCAM-1 expression (P < 0.05). Atorvastatin exerted significant antiatherogenic effects, and 99mTc-cAbVCAM1-5 lesion uptake was significantly reduced in 35-wo old atorvastatin-treated mice, as indicated by ex vivo y–well counting and autoradiography (P < 0.05). SPECT imaging quantification based on contrast-enhanced CT was reproducible (interexperimenter intraclass correlation coefficient, 0.97; intraexperimenter intraclass correlation coefficient, 0.90), and yielded results that were highly correlated with tracer biodistribution (r = 0.83; P < 0.0001). Therefore, reduced 99mTc-cAbVCAM1-5 uptake in atorvastatin-treated mice was successfully monitored noninvasively by SPECT/CT imaging (0.87 ± 0.06 vs. 1.11 ± 0.09 percentage injected dose per cubic centimeter in control group, P < 0.05). Conclusion: 99mTc-cAbVCAM1-5 imaging allowed the specific, sensitive, and reproducible quantification of VCAM-1 expression in mouse atherosclerotic lesions. 99mTc-cAbVCAM1-5 therefore exhibits suitable characteristics for the evaluation of novel antiatherogenic agents.

Key Words: 99mTc-cAbVCAM1-5; atherosclerosis; VCAM-1; molecular imaging

DOI: 10.2967/jnumed.114.143792

Atherosclerosis constitutes a worldwide health challenge (1). Despite major advances in imaging technologies (2), a major need for imaging probes targeting vulnerable plaque still exists. Such a tool could be used for diagnosis and prognosis as well as for the monitoring of treatment efficacy (3). A major criterion for the identification of vulnerable plaque is inflammation (4). Vascular cell adhesion molecule 1 (VCAM-1) plays a major role in the infiltration of inflammatory cells into atherosclerotic lesions (5). Indeed, in human atherosclerotic lesions, VCAM1 expression was observed at the level of the luminal endothelium as well as on neovessels, macrophages, and activated smooth muscle cells of advanced lesions (5–7). Therefore, the assessment of VCAM-1 expression levels in atherosclerotic plaques could potentially be highly relevant for identifying prone-to-rupture lesions (8). Because of the small size and location of vulnerable plaque, imaging agents with optimal characteristics are required. Single-domain antibody-derived radiotracers that originally were developed in the field of oncology (9) have recently been proposed by our group as a new class of imaging agent with optimal characteristics for cardiovascular imaging (10), and the radiolabeled anti-VCAM-1 camel antibody fragment 99mTc-cAbVCAM1-5 compound was selected among 10 VCAM-1–specific single-domain antibodies as the most potent candidate. Accordingly, aortic plaques were successfully visualized noninvasively by SPECT in an apolipoprotein E (ApoE)–deficient mouse model of atherosclerosis, with binding specificity being further demonstrated by in vivo competition experiments. Importantly, the production and selection processes of VCAM-1 single-domain antibody were specifically designed to produce cross-reactive murine and human binders. The nanomolar affinity of 99mTc-cAbVCAM1-5 for both human and murine VCAM-1 therefore makes the tracer potentially suitable for clinical translation (10).

The main objective of the present study was to investigate the sensitivity of 99mTc-cAbVCAM1-5 for the imaging of VCAM-1 expression in murine atherosclerotic lesions. High sensitivity is a key requirement for vulnerable plaque imaging and for preclinical assessment of the efficacy of novel antiatherogenic therapies. In accordance with the major role of inflammatory processes in the development of vulnerable plaque, the antiinflammatory effect of new therapeutic agents targeting the lipid profile, such as cholesterol esterase transfer protein inhibitors, is currently being investigated.

Sensitivity of 99mTc-cAbVCAM1-5 Imaging • Broisat et al.
In addition, therapeutic interventions aimed at directly targeting the inflammatory process are also under evaluation (3) using drugs such as methotrexate, canakinumab, or losmapimod (12–14). A specific and sensitive imaging agent targeting the inflammatory process in atherosclerotic lesions would therefore be of great relevance for the evaluation of novel antiatherogenic agents.

Statins are well established and widely used therapeutics in clinical practice, and atorvastatin has previously been used for the evaluation of new imaging agents in mouse models of atherosclerosis (15–17). In the present preclinical study, atorvastatin was used to evaluate the potential of \(^{99m}\)Tc-cAbVCAM1-5 for monitoring treatment efficacy in ApoE-deficient mice.

MATERIALS AND METHODS

Animal Model

All experimental procedures were in accordance with institutional guidelines and approved by the Animal Care and Use Committee (Comité d’Éthique) of the University of Grenoble.

Twelve 40-wk-old female ApoE-deficient mice (Charles River) fed a western-type diet were used for the ex vivo comparison between \(^{99m}\)Tc-cAbVCAM1-5 uptake in atherosclerotic lesions and VCAM-1 expression.

Eighteen female ApoE-deficient mice were used for noninvasive evaluation of a reference therapy. At the age of 15 wk, mice were fed either a western diet (control group, \(n = 9\)) or a western diet supplemented with a reference therapy (0.01% atorvastatin) (treated group, \(n = 9\)). In these 2 groups, average food consumption and animal weight were assessed weekly and blood sampling was performed before and 10 wk after the onset of the western diet for total cholesterol determination (BioMerieux). The effect of the statin therapy on \(^{99m}\)Tc-cAbVCAM1-5 uptake in atherosclerotic lesions was evaluated in vivo using longitudinal SPECT/CT imaging on 25- and 35-wk-old mice and ex vivo by \(\gamma\)-well counting and autoradiography.

Radiolabeling

cAbVCAM1-5 labeling with \(^{99m}\)Tc was performed as previously described (10). Briefly, \(\left[{^{99m}\text{Tc}}(\text{H}_2\text{O})_3\text{(CO)}_3\right]^+\) \(\text{[Tc-tricarbonyl]}\) was synthesized by adding 1 mL of \(^{99m}\)TcO\(_4^–\) solution to an Isolink kit (PSI). The vial was incubated at 100°C for 20 min and neutralized with HCl. Then, 0.5 mL of \(^{99m}\)Tc-tricarbonyl was added to 50 µg of cAbVCAM1-5 and 50 µL of 50 mM carbonate buffer, pH 8.0, and this mixture was incubated for 90 min at 50°C. The \(^{99m}\)Tc-cAbVCAM1-5 solution was further gel-filtrated on Sephadex G25 (NAP-5; GE Healthcare) and filtered (0.22-µm Milllex; Millipore). Radiochemical purity, determined by reverse-phase high-performance liquid chromatography, was more than 95% up to 6 h after radiolabeling.

\(^{99m}\)Tc-cAbVCAM1-5 Uptake Versus VCAM-1 Expression

\(^{99m}\)Tc-cAbVCAM1-5 uptake in atherosclerotic lesions and VCAM-1 expression level were determined using autoradiographic imaging and immunohistochemistry, respectively (\(n = 12\)). Three hours after intravenous injection of 37 ± 3 MBq (mean ± SD), mice were euthanized using CO\(_2\). The aortic arch was cleaned in 10% formalin. The aortic arch was cut into two parts (ascending and descending aorta). Small curvature of the aortic arch was preferred for it allowed simultaneous examination of several lesions, located in the ascending aorta; small curvature of the aortic arch; innominate, left common carotid, and left subclavian arteries; and descending aorta.

Autoradiography. Autoradiography was performed using overnight exposure with a phosphor imager (BAS-5000; Fujifilm). All slices were then stained using standard hematoxylin-eosin-safran trichrome staining (HES) and were digitalized, and HES and autoradiographic images were coregistered using GIMP2 and ImageJ software. Regions of interest were drawn on atherosclerotic lesions on the basis of HES staining. Internal references with known amounts of radioactivity were used to express tracer activity as percentage injected dose (%ID) per gram after background and decay correction.

Immunohistochemistry. VCAM-1 immunostaining (sc-1504; Santa Cruz Biotechnology) was performed as previously described (10) on slices adjacent to those used for autoradiography and HES staining. The VCAM-1 expression level in atherosclerotic lesions (\(n = 94\)) was ranked as low, moderate, or strong by a trained observer masked to the autroradiographic images. This analysis was reproduced 2 mo later by the same observer to assess the reproducibility of the methodology.

Noninvasive Evaluation of a Reference Therapy

SPECT/CT Imaging. SPECT/CT acquisitions were performed 2 h after an intravenous injection of 55 ± 5 MBq (mean ± SD) of...
99mTc-cAbVCAM1-5. The mice were anesthetized using 1.5% isoflurane in a 1:1 mixture of room air and oxygen and then were placed in a temperature-controlled bed for SPECT/CT acquisitions focused on the thoracic region (nanoSPECT; Bioscan). First, the helicoidal SPECT acquisition was performed with 4 heads equipped with multipinhole collimators (nine 1.4-mm-diameter pinholes per head) using 24 projections and 45 min of acquisition. Then, a fast 1.5-min-long CT acquisition was performed immediately after retroorbital injection of 150 μL of a vascular contrast agent (ioxaglate [Hexabrix]; Guerbet), using the following acquisition parameters: 65 kVp, 180 projections, and 500 ms per projection. Contrast-enhanced CT and SPECT acquisitions were reconstructed, fused, and quantified using dedicated software (InVivoScope; inviCRO, LLC).

**SPECT/CT Quantification.** SPECT quantification based on contrast-enhanced CT was performed masked to the SPECT images. Briefly, 4 volumes of interest (VOIs) of 2.2 mm³ each were drawn at the level of the aortic sinus and ascending aorta on the basis of the enhanced CT images. 99mTc-cAbVCAM1-5 activity was expressed as %ID/cm³, and uptake in atherosclerotic lesions was defined as the maximum value from quantification of 4 VOIs. Moreover, to assess the inter- and intraobserver variability, 35-wk SPECT images were further quantified by 3 additional independent experimenters, and this quantification was reproduced 2 wk later by one of the experimenters.

**Ex Vivo Quantification.** After SPECT/CT imaging, anesthetized mice were euthanized using CO₂ and ascending aortas, including the aortic sinus, were carefully harvested along with major organs. Tissue samples were weighed, and their activity was determined by γ-well counting (Wizard²; Perkin). The results were corrected for background and decay and expressed as %ID/g. Adjacent transversal 40- and 10-μm-thick cryosections were obtained at the level of the aortic sinus for autoradiographic imaging and immunostaining, respectively, and autoradiography quantification was performed after HES staining. Regions of interest were also used to determine lesion area in square millimeters. 99mTc-cAbVCAM1-5 uptake was expressed as %ID per gram of lesion (“concentration”) based on internal references. Alternatively, lesion volume in the analyzed slice was determined as the product between its surface and the slice thickness (40 μm), and 99mTc-cAbVCAM1-5 uptake was then expressed as %ID present in the analyzed slice (“total uptake”).

**Statistical Analysis**

All results are presented as mean ± SEM. F testing was used for variance comparisons. The Student t, Mann–Whitney U, Pearson, intraclass correlation coefficient, and χ² tests were used for paired or unpaired datasets with equal variance, unpaired datasets with unequal variance, correlation analysis, and inter- or intraexperimenter variability, respectively. Differences were considered significant at a P level of less than 0.05.

**RESULTS**

**99mTc-cAbVCAM1-5 Uptake Versus VCAM-1 Expression**

Heterogeneous VCAM-1 expression levels were observed after immunostaining of longitudinal slices from the aortic arch of ApoE−/− deficient mice (Figs. 1A and 1C). VCAM-1 was expressed by endothelial as well as intraplaque cells. Intraobserver ranking of VCAM-1 expression level was found to be reproducible (κ = 0.70). Robust 99mTc-cAbVCAM1-5 uptake was observed after autoradiographic imaging of VCAM-1–positive lesions (Figs. 1B and 1D). Autoradiography quantification confirmed the relationship between 99mTc-cAbVCAM1-5 uptake and the level of VCAM-1 expression (Fig. 1E). A graded tracer uptake of 1.4 ± 0.2, 2.5 ± 0.2, and 3.2 ± 0.3 %ID/g was observed in low, moderate, and strong VCAM-1–expressing lesions, respectively (P < 0.001 between low and moderate or strong, and P = 0.029 between moderate and high).

**Noninvasive Evaluation of a Reference Therapy**

**Lesion Extent.** The results are presented in Table 1 and Supplemental Figure 1. Similar cholesterol levels were observed between treated and control animals before they were switched from chow to a western diet containing atorvastatin (treated) or not (control) (20.3 ± 2.2 vs. 18.8 ± 2.2 mmol/L, P = not statistically significant [NS]). Average atorvastatin intake was 12.9 ± 0.2 mg/kg/d/animal day.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Treated</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol, chow diet (mmol/L)</td>
<td>20.3 ± 2.2</td>
<td>18.8 ± 2.2</td>
<td>NS</td>
</tr>
<tr>
<td>Total cholesterol, western diet (mmol/L)</td>
<td>85.5 ± 8.1</td>
<td>60.7 ± 6.6</td>
<td>−29.1 (P = 0.034)</td>
</tr>
<tr>
<td>Lesion area (mm²)</td>
<td>1.07 ± 0.11</td>
<td>0.70 ± 0.07</td>
<td>−33.9 (P = 0.011)</td>
</tr>
</tbody>
</table>

TABLE 1

Effect of Treatment on Lesion Extent
and resulted in a significant 29.1% decrease in total cholesterol level in the atorvastatin-treated group in comparison with the control group (60.7 ± 6.6 vs. 85.5 ± 8.1 mmol/L; *P = 0.034). Lesion extent in the aortic sinus was significantly reduced by 39.9% in the treated group in comparison to that in the control group (0.70 ± 0.07 vs. 1.07 ± 0.11 mm²; *P = 0.011) (Table 1; Supplemental Fig. 1 [supplemental materials are available at http://jnm.snmjournals.org]). Finally, modest variations in VCAM-1 expression in the aortic sinus were observed between control and treated animals after immunohistochemistry (Supplemental Fig. 1).

In Vivo SPECT/CT Imaging. \(^{99m}\)Tc-cAbVCAM1-5 allowed the noninvasive monitoring of atorvastatin effect on atherosclerosis. \(^{99m}\)Tc-cAbVCAM1-5 uptake in aortic lesions was readily visible on SPECT images (Fig. 2), and the trend toward a reduction of \(^{99m}\)Tc-cAbVCAM1-5 uptake that was observed in 25-wk-old atorvastatin-treated mice (0.83 ± 0.09 %ID/cm³ vs. 0.97 ± 0.06 %ID/cm³ in the control group, *P = 0.035) reached statistical significance at 35 wk (0.87 ± 0.06 %ID/cm³ vs. 1.11 ± 0.09 %ID/cm³ in the control group, *P = 0.035). Enhanced-CT acquisitions allowed accurate delineation of the ascending aorta in all animals, and enhanced-CT–based SPECT quantification was reproducible, with inter- and intraexperimenter intraclass correlation coefficient (ICC) (C).

![FIGURE 3. SPECT/CT quantification. Reduction of \(^{99m}\)Tc-cAbVCAM1-5 uptake in treated mouse aorta was successfully monitored in vivo by SPECT/CT imaging (A). Furthermore, SPECT analysis based on contrast-enhanced CT provided robust quantifications, as determined by intraexperimenter correlation (B) and inter- and intraexperimenter intraclass correlation coefficient (ICC) (C).](image)

Ex Vivo SPECT/CT Imaging. \(^{99m}\)Tc-cAbVCAM1-5 uptake in atherosclerotic lesions was readily observable at the level of the aortic sinus (Supplemental Figs. 1A–1D). A strong and statistically significant 41.5% decrease in \(^{99m}\)Tc-cAbVCAM1 uptake in atherosclerotic lesions was readily visible on SPECT/CT imaging (A). Furthermore, SPECT/CT image quantification correlated significantly with total lesion extent in the aortic sinus as determined by autoradiography (*P = 0.51; *P = 0.04) rather than to \(^{99m}\)Tc-cAbVCAM1 concentration or to lesion area (*P = NS) (Table 3). The results from SPECT/CT image quantification correlated significantly with total \(^{99m}\)Tc-cAbVCAM1 uptake in aortic sinus lesions as determined by autoradiography (*P = 0.51; *P = 0.04) rather than to \(^{99m}\)Tc-cAbVCAM1 concentration or to lesion area (*P = NS for both) (Figs. 4B–4D).  

DISCUSSION

Atorvastatin significantly reduced the extent of lesions in the aortic sinus of ApoE-deficient mice, and this effect was successfully monitored noninvasively using \(^{99m}\)Tc-cAbVCAM1-5 molecular imaging.

### TABLE 2

<table>
<thead>
<tr>
<th>Site</th>
<th>Control</th>
<th>Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascending aorta</td>
<td>1.2 ± 0.1</td>
<td>0.9 ± 0.1*</td>
</tr>
<tr>
<td>Blood</td>
<td>0.6 ± 0.1</td>
<td>0.5 ± 0.0</td>
</tr>
<tr>
<td>Heart</td>
<td>0.3 ± 0.0</td>
<td>0.3 ± 0.0</td>
</tr>
<tr>
<td>Lung</td>
<td>1.7 ± 0.1</td>
<td>1.8 ± 0.1</td>
</tr>
<tr>
<td>Liver</td>
<td>1.5 ± 0.1</td>
<td>1.4 ± 0.1</td>
</tr>
<tr>
<td>Skeletal muscle</td>
<td>0.1 ± 0.0</td>
<td>0.3 ± 0.1</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>0.7 ± 0.2</td>
<td>0.7 ± 0.1</td>
</tr>
<tr>
<td>Thyroid</td>
<td>1.2 ± 0.2</td>
<td>0.9 ± 0.2</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.7 ± 0.1</td>
<td>0.7 ± 0.1</td>
</tr>
<tr>
<td>Bile</td>
<td>0.4 ± 0.0</td>
<td>0.5 ± 0.1</td>
</tr>
<tr>
<td>Kidney</td>
<td>138.7 ± 8.6</td>
<td>165.0 ± 6.8</td>
</tr>
<tr>
<td>Spleen</td>
<td>8.8 ± 0.7</td>
<td>7.9 ± 0.5</td>
</tr>
<tr>
<td>Thymus</td>
<td>2.1 ± 0.2</td>
<td>1.8 ± 0.2</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>4.0 ± 0.4</td>
<td>4.1 ± 0.7</td>
</tr>
<tr>
<td>Lymph node</td>
<td>2.8 ± 0.3</td>
<td>2.7 ± 0.2</td>
</tr>
</tbody>
</table>

* *P = 0.015 vs. control group.

Data are %ID/g (mean ± SEM).
imaging with high reproducibility. $^{99m}$Tc-cAbVCAM1-5 is therefore a specific, sensitive, and reproducible tool for the imaging of VCAM-1 expression in murine atherosclerotic lesions.

**Effect of Statin Therapy**

The antiatherosclerotic effects of statins are mediated mainly by their cholesterol-lowering properties, leading to reduced plaque volume (18). In addition, statins also exert pleiotropic effects that go beyond the drop in plasma cholesterol and result mainly in an inhibition of inflammatory processes responsible for vulnerable plaque development (19,20). However, depending on the dose and duration of the treatment and on study design, the reduction in plasma cholesterol, plaque volume, and inflammatory markers is not always consistently or concomitantly observed in experimental studies. Indeed, in an ApoE-deficient mouse model of carotid artery lesions induced by perivascular collar placement, Bot et al. observed that a low dose of atorvastatin (0.003% w/w) significantly reduced lesion size by 40% despite no reduction in total plasma cholesterol or macrophage-positive areas (15). Conversely, a 12-wk atorvastatin treatment (1 mg/kg/d) resulted in a significant reduction in the circulating inflammatory markers interleukin-6 and monocyte chemoattractant protein-1 as well as macrophage infiltration in aortic lesions of apoE-deficient mice despite no significant change in plasma cholesterol and plaque area (21).

The apoE-deficient mice fed a western diet in the present study had a mean total blood cholesterol level of 85.5 ± 8.1 mmol/L, in good accordance with the 28–114 mmol/L range reported for a similar model by Nakashima et al. (22). Supplementation of the western diet with 0.01% w/w atorvastatin resulted in an expected administered dose of about 10 mg/kg/d (16). Atorvastatin significantly decreased total cholesterol by 29% and lesion size by 40%. These results are in accordance with the range of atorvastatin-induced modifications reported by other groups (16,17,22). However, Nachtigal et al. (24) found no significant change in VCAM-1 lesion expression in double-knock-out low-density lipoprotein receptor–deficient ApoE-deficient mice in the presence of atorvastatin at a dose similar to that used in the present study.

Overall, atorvastatin administered at a dose of 0.01% w/w for 20 wk to ApoE-deficient mice fed a western diet therefore had significant antiatherogenic effects that allowed evaluation of the potential of $^{99m}$Tc-cAbVCAM1-5 for treatment effect monitoring.

**Sensitivity of $^{99mTc}$-cAbVCAM1-5 Imaging**

$^{99mTc}$-cAbVCAM1-5 uptake occurred in atherosclerotic lesions and in lymphoid organs constitutively expressing VCAM-1 after tracer injection to ApoE-deficient mice fed a western diet, in accordance with previously published results (10). Autoradiography and immunohistochemistry indicated that $^{99mTc}$-cAbVCAM1-5 uptake in atherosclerotic lesions significantly increased together with the level of VCAM-1 expression. Importantly, $^{99mTc}$-cAbVCAM1-5 lesion uptake was significantly reduced in 35-wk-old atorvastatin-treated mice as indicated by ex vivo γ-well counting and autoradiography as well as in vivo noninvasive SPECT/CT molecular imaging. In vivo image quantification was reproducible and yielded results that correlated strongly with tracer biodistribution as determined ex vivo.

More precisely, VOIs from in vivo images were reproducibly drawn at the level of the aortic sinus on the basis of enhanced-CT images. In the hypothesis that the VOI exclusively contained atherosclerotic lesional tissues and according to the fact that $^{99m}$Tc-cAbVCAM1-5 uptake in murine atherosclerotic lesion significantly increased together with the level of VCAM-1 expression, SPECT quantification would then have directly reflected the level of VCAM-1 expression in atherosclerotic lesions. However, because of the relatively small size of atherosclerotic lesions, and despite the use of a state-of-the-art, submillimeter-resolution system, partial-volume effect necessarily occurred during SPECT imaging of murine aortic plaques. Therefore, the VOI used for the assessment of tracer uptake in atherosclerotic lesions contained a mixture of the various tissues composing the aortic sinus—that
is, atherosclerotic lesions, normal vessel wall, and blood—rather than the atherosclerotic lesion only. Consequently, the total activity in a VOI, and therefore the result of in vivo quantification, depended not only on the level of VCAM-1 expression in the lesions but also on the volume of lesions included in the VOI, and therefore lesion extent. This was demonstrated in the present study by the fact that the results from SPECT/CT image quantification correlated significantly with $^{99m}$Tc-cAbVCAM1 total uptake in aortic sinus lesions as defined by the product of $^{99m}$Tc-cAbVCAM1 concentration in lesion-by-lesion volume, rather than with either of these 2 parameters considered separately. In conclusion, $^{99m}$Tc-cAbVCAM1-5 SPECT/CT imaging allowed the sensitive and reproducible noninvasive quantification of the net effect of a reference statin therapy on lesion size and inflammation in the apoE-deficient mouse model of atherosclerosis.

Comparison with Other Radiotracers and Molecular Targets

The sensitivity of $^{99m}$Tc-cAbVCAM1-5 imaging favorably compared with previously evaluated radiotracers. In a rabbit model of atherosclerosis, Haider et al. observed a decrease in the uptake of 2 SPECT agents directed against matrix metalloproteinases and apoptosis (annexin-A5) after treatment with fluvastatin (25). Although SPECT image quantification was not performed, these qualitative visual observations were further confirmed by quantitative ex vivo analysis. Similarly, a significant 30% reduction in 18F-4V was found by in vivo PET image quantification in a model similar to that used in the present study (23). Several studies have investigated the potential of 18F-FDG for the noninvasive assessment of treatment efficacy. Such potential has been validated in rabbits using the antioxidant probucol (26), thereby allowing the use of 18F-FDG for the evaluation of novel therapeutics in preclinical studies (27,28) and clinical studies (12,29). However, high myocardial uptake remains a potential limitation for the imaging of coronary lesions with 18F-FDG despite the use of imaging protocols aimed at reducing myocardial tracer uptake (30).

VCAM-1 protein is strongly and specifically expressed during the inflammatory process and therefore constitutes a highly relevant target for vulnerable plaque imaging, similarly to other inflammatory markers such as macrophages. Other biologic processes related to plaque rupture such as apoptosis, matrix degradation, or neoangiogenesis (31) have been proposed as potential targets. These processes occur at different times and intra-plaque locations over the course of plaque development. Ultimately, prospective clinical trials will be needed to select the most appropriate target and corresponding imaging agent.

CONCLUSION

SdAbs-derived radiotracers were initially developed in the field of oncology, and a first phase I clinical trial is currently being performed with an anti–human epidermal growth factor receptor 2 radiotracer for PET imaging of breast cancer patients. Anti-VCAM-1 single-domain antibody has extended the field of single-domain antibody imaging to cardiovascular applications. As demonstrated in the present study, $^{99m}$Tc-cAbVCAM1-5 is a sensitive tool for the noninvasive imaging of atherosclerosis. Indeed, $^{99m}$Tc-cAbVCAM1-5 uptake in mouse atherosclerotic lesions correlated with the level of VCAM-1 expression, and the effect of a reference therapy was successfully and reproducibly monitored noninvasively by SPECT/CT imaging quantification. $^{99m}$Tc-cAbVCAM1-5 therefore exhibits suitable characteristics for evaluation of novel antiatherogenic agents.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. This work was partly funded by the French program Investissement d’Avenir run by the Agence Nationale pour la Recherche, grant ANR-11-INBS-0006 (Infrastructure d’avenir en Biologie Santé), and grant ANR-09-TECS-017-01 (PLAQUIMAG). No other potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

Antony Coradin, Pierre-Francois Meyer, and Audrey Genoud, students of Grenoble University, were involved in data collection and analysis during their training course in the Radiopharmaceutiques Biocliniques Laboratory.

REFERENCES


